Physician profile
Katherine Gregory
NPI 1902954308
$3,425.15
in general payments reported to CMS, 2019-2025
28 companies · $573 in 2025
The $573 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $59.32 · 2021: $1,003 · 2022: $693 · 2023: $499 · 2024: $390 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,124.27 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $375.04 | 2021-2025 | |
| Therapeuticsmd, INC. | $310.36 | 2019-2022 | |
| Astellas Pharma US INC | $299.73 | 2023-2025 | Veozah |
| Avion Pharmaceuticals | $255.88 | 2021-2022 | |
| Ethicon US, LLC | $129.69 | 2019-2022 | |
| Coopersurgical, INC. | $126.71 | 2022-2023 | Paragard T 380a, Endosee |
| Bayer Healthcare Pharmaceuticals INC. | $115.86 | 2019-2023 | |
| Exeltis, USA INC. | $84.53 | 2025 | Slynd |
| Pfizer INC. | $75.79 | 2021-2023 | |
| Organon LLC | $68.71 | 2024 | |
| Myovant Sciences INC. | $64.95 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $50.97 | 2025 | |
| Shield Therapeutics INC | $37.26 | 2023 | Accrufer |
| Ascend Therapeutics US, LLC | $32.49 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $27.57 | 2025 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $25.95 | 2021 | |
| Novo Nordisk INC | $23.86 | 2025 | Ozempic |
| Merck Sharp & Dohme LLC | $23.80 | 2021 | |
| Becton, Dickinson and Company | $21.63 | 2024 | |
| Hologic Sales and Service, LLC | $20.65 | 2020 | |
| Sumitomo Pharma America, INC. | $19.95 | 2024 | Myfembree |
| Evofem Biosciences, INC. | $19.85 | 2022 | |
| Vertical Pharmaceuticals, LLC | $19.28 | 2019 | |
| Lupin INC. | $18.83 | 2020 | |
| Minerva Surgical, INC | $17.60 | 2024 | |
| Allergan, INC. | $17.00 | 2019 | |
| Axonics, INC. | $16.94 | 2024 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.